Background: Bioresorbable vascular scaffolds (BVS) represent the next generation in stent technology, however long-term efficacy and safety data is lacking. Method: Consecutive patients from October 2012 to December 2013 were included in a single centre registry. Immediate, 30-day, 1-year and yearly thereafter clinical follow-up and event rates were recorded to a median of 3.5 years. Results: 69 patients with a mean age of 66 ± 9 years (male 77%) underwent BVS implantation. Indications for coronary angiogram were STEMI (2%), NSTEMI (25%), unstable angina (23%), stable angina (34%), staged procedure (13%) and other (3%). There were 85 lesions (mean 1.2 per patient) with a total of 97 BVS inserted. Lesion category according to ACC/AHA were; type A (1%), B1 (19%), B2 (60%) and C (20%). During follow-up there were 3 cases (4.3%) of definite stent thrombosis (ST) and one case of early probable ST. No events occurred between 0-30 days, 1 (1.2%) between 31 days to 1 year, and 5 (5.9%) between 1-3.5 years. Target vessel revascularisation (TVR) 1 (1.2%) between 30 days to one year, and 4 (4.7%) between 1-3.5 years. Cumulative TVR rate at latest follow-up was 5.9%. Cumulative death rates at 30 days, 1 year and median follow-up were 1.4%, 2.8% and 2.8% respectively. Conclusions: This single centre real world experience suggests acceptable long-term safety and efficacy of the Absorb® bioresorbable vascular scaffold. However, more data is required beyond 3.5 years, ideally in the form of a randomised control trial.